Today urinary excretion of estrogen äs an indicator of possible pregnancies at risk is an accepted parameter. For a long time excretion of estrogen was considered äs a so-called fetoplacental indicator; since both fetus and placenta participate in estriol synthesis. However, recent findings indicate [7, 22, 23] that the fetus is, to some extent, independent of the placenta äs far äs the synthesis of estriol precursors is concerned. It has also been demonstrated that the capacity of the placenta to form aromatic compounds is not decreased but rather elevated in severely impaired nutrition [21] . Heüce decreased estrogen excretion is more probably due to limited synthesis in the fetus than in the placenta. The lack of placental sulfatase is an exception that is hardly of quantitative importance [6, 8] . Hence the rate of estrogen excretion may be considered a fetal rather than a fetoplacental parameter. Usually an impairment of the nutritive function of the placenta that is chronic in nature is the basis of the endocrinologically assayable danger to the fetus. If urinary estrogen excretion is decreased it must be assumed that the fetus has already been damaged. Hence for perinatal diagnostic purposes it is desirable to use a purely placental indicator that might indicate danger earlier than estrogen excretion and that permits us to distinguish between fetal and placental malfunction. Three hormone tests are usually applied: HPL (human placental lactogen) in serum; pregnandiol in urine äs an indicator of progesteron metabolism and plasma progesteron. HPL indicates the rate of proteinsynthesis in the placenta and pregnandiol its steroid biosynthesis. The introduction of radioimmunological tests for HPL has feduced pregnandiol determinations with their well known drawbacks related to urinary analyses. Pregnandiol determinations very often gave false normal J. Perinat. Med. 3 (1975) 
Today urinary excretion of estrogen äs an indicator of possible pregnancies at risk is an accepted parameter. For a long time excretion of estrogen was considered äs a so-called fetoplacental indicator; since both fetus and placenta participate in estriol synthesis. However, recent findings indicate [7, 22, 23] that the fetus is, to some extent, independent of the placenta äs far äs the synthesis of estriol precursors is concerned. It has also been demonstrated that the capacity of the placenta to form aromatic compounds is not decreased but rather elevated in severely impaired nutrition [21] . Heüce decreased estrogen excretion is more probably due to limited synthesis in the fetus than in the placenta. The lack of placental sulfatase is an exception that is hardly of quantitative importance [6, 8] . Hence the rate of estrogen excretion may be considered a fetal rather than a fetoplacental parameter. Usually an impairment of the nutritive function of the placenta that is chronic in nature is the basis of the endocrinologically assayable danger to the fetus. If urinary estrogen excretion is decreased it must be assumed that the fetus has already been damaged. Hence for perinatal diagnostic purposes it is desirable to use a purely placental indicator that might indicate danger earlier than estrogen excretion Curriculum vitae Dr. rer and that permits us to distinguish between fetal and placental malfunction. Three hormone tests are usually applied: HPL (human placental lactogen) in serum; pregnandiol in urine äs an indicator of progesteron metabolism and plasma progesteron. HPL indicates the rate of proteinsynthesis in the placenta and pregnandiol its steroid biosynthesis. The introduction of radioimmunological tests for HPL has feduced pregnandiol determinations with their well known drawbacks related to urinary analyses. Pregnandiol determinations very often gave false normal results [11] . The value of HPL determinations has invited contradictory opinions [3, 4, 12, 16, 18, 19, 20] . Our own data also indicate that HPL in addition to estrogen determinations does give Information on placental function but that this represents no gain in time (unpublished data). Time, however, is of utmost importance. We have retained the use of urinary analysis. Our results with pregnandiol using a previously reported method [24] do not agree with those of KELLER [11] . We asked whether estriol excretion was really a fetal parameter. Hence both estrogen and pregnandiol were determined in 24-houn urine samples. A total of 2500 combined hormone analyses were performed in 500 cases from which the 222 reported pregnancies at risk were chosen.
l Material and Method
Estrogen and pregnandiol were determined äs described previously [24, 25] using internal Standards. The method is reliable. Normal values were obtained from a large number of normal women between the 20th and 40th weeks of pregnancy [24, 25] . 24-hour urines were examined for creatinine (picric acid method, TECHNICON autoanalyser) to test for correct urine collections. Not only "normal" creatinine excretion but also the constant rate of intraindividual excretion served äs criteria. Only 24-hour urines were tested. Only the following pregnant women were included:
1. At least 3 hormone tests 1 ). 2. Last hormone analysis at the earliest one week before the end of pregnancy. 3. Pregnancy at risk according to case history or finding; with suspicion of chronic impairment of the feto-placental unit. 4. No acute renal disease and no penicillin treatment [26] .
Hormone excretion was considered to be pathological if x ) Only a few exceptions were made; e. g. in severe cases, when pregnancy was terminatgd for clinical reasons and the very low hormone values, or if suspicion of fetal death was confirmed endocrinologically.
1. there was no normal rise in hormone excretion; but a stagnant level, particularly for estrogen -for a period of at least 4 weeks, even if this was within the normal ränge 2. there was a fall in hormone excretion within a few days, even within the normal ränge, to less than 50% of the initial value, 3. there was a prolonged slow decline in hormone excretion -even within the normal ränge 4. many of the values were within a doubtful pathological ränge [8, 9] or below that ränge 5. particularly estrogen excretion showed "heterogeneous oscillations", this being a pattern of exretion that occurs frequently in less severe cases of intrauterine growth retardation, that can only be identified at high frequencies of analysis and that i s discussed below.
The requirement for "correct Information" was met if In none of these cases with normal hormone values was a small for date infant delivered.
Risk groups and types of risk
We shall deal with the four possible hormone combinations separately. Risk groups will be delineated at the same time. The four groups at risk are devided according to the type of risk. The largest number of SGA infants is found in risk group IV (pathological excretion of both hormones). Results are summarized in Tab. II.
Risk group I
As expected this includes mainly pregnancies that were at greater risk because of case history or postmaturity but resulted after normal clinical courses in a healthy füll term baby. The 15 cases of light, mostly monosymptomatic (slight hypertension) EPH.gestosis belong here. As already mentioned the risks "imminent premature delivery" and "postmaturity" may belong to group I and cannot be securely distinguished by combined hormone determinations. When deciding whether estrogen excretion is rising (term has not yet occurred) or falling (postmature) it must be remembered that daily variations in estrogen excretion are about 20% (see below). As expected there is no intrauterine growth retardation in group I.
Risk group II
The hormonal picture is typical for EHP gestosis and is most frequently found if examination is begun early äs soon äs signs of hypertonia are observed. In light or well treated cases there is no change in the excretion of hormones up to the end of gestätion. Predominantly a normal child is delivered. Only 6 out of 66 maldeveloped children showed the hormone picture of group II. In three of these an EPH gestosis was also present, in two bleeding occurred and in one premature labour set in. Untreated EPH gestosis terminates within weeks or months mostly in group IV indicating fetal in Jury äs judged from altered estrogen excretion. There is a very small number of cases with premature labor which corresponds with a small correlation between imminent premature labor and impairment of placental function. Intrauterine growth retardation was found in 11.5%. This frequency indicated that this type of risk is not always discovered by estrogen determinations alone.
Risk group III
Injury of the fetus without demonstrable endocrine impairment of placental function (pathological placental parameter) should be the exception, rather than the rule. The small number of cases thus agrees with our expectation. Yet this hormone pattern, in comparison to that of group II, indicates a greater degree of risk, äs shown by the greater frequency of SGA infants in group III. The hormone excretion in anencephaly is typical for group III (one case). Hence pathological estrogen excretion with normal excretion of pregnandiol should raise suspicion of this anomaly. The six pregnancies with intrauterine SGA infants in group III consisted of 2 EPH gestoses, three premature labors and one functional disturbance of the placenta without other Symptoms.
Risk group IV
As expected this contains the largest number of cases, severe gestoses, most infants small for date and the smallest number of false pathological results (one case). The risk type "EPH gestosis" and "suspected impairment of nutritive placental function" form 67.3% of all cases of this group. A total of 63 SGA infants was born. The mothers of 51 of these had the hormone excretion of risk group IV (frequency 55.4%). In 24 of these 51 mothers a usually severe EPH gestosis was present; in 18 the case history or the present state indicated impairment of the nutritive function of the placenta; in the remaining 9 premature labor or hemorrhage were found. The relatively large percentage of SGA infants whose mothers, except for a history of placental insufficiency or low fundus, showed no clinical signs of chronic placental impairment, was surprising. weeks of pregnancy Variations that exceed these values, even though they lie within the norm, must be viewed s pathological. We suggest that this be called "heterogeneous variations". Case 2 also was a severe EPH gestosis with no hormonal control or treatment. The dead infant (1650 g, 44 cm) requires no comment.
Other problems a) Critical limit of hormone excretion
Some workers [17] consider an endocrine parameter to be not only normal or pathological but assign it a certain weight for estimating the risk, by evaluating its transverse position according to a point System, (e. g. estrogen excretion = low normal = l point, in dubious pathological r nge 2 points etc.). This leads to the following question: Is there a critical lower limit for estrogen excretion below which it is better to terminate pregnancy, i. e. for which chances for survival are better outside the uterus than within. Our data cohtain 10 perinatal deaths, of which one was an anencephalus. Another two can be eliminated since they died before the 30th week of gestation. Of the remaining 7, in four the fetus died in utero, in 3 cases within 12 days after birth. Hence there are very few cases. Fig. 3 shows the lowest estrogen value found in 8 pregnancies between the 30th and 40th week. Evidently there is a crossing over of values, the 
b) Fall in estrogen, time factor, diabetes
If we define a fall in estrogen äs a sudden precipitous decrease from one day to the next without return to normal values, then this was never observed in living fetuses. If it does occur the fetus is most probably dead or dying. It follows that the often discussed time factor in the delay with which laboratory results are obtained is unimportant in terms of hours or even days. From that point of view plasma against 24-hour urine analyses are equally valuable. It is much more important to have precise data determined repeatedly so-that the time course of excretion can be assessed. The only exception in our opinion are diabetic mothers in the last weeks of pregnancy where daily estrogen determinations and less so pregnandiol determinations, are of certain value.
Discussion
The most important result of this work is the frequently observed temporal shift between decreased estrogen excretion and pregnandiol excretion in chronic impairment of the nutritive function of the placenta. This can only be understood if we assume that estrogen excretion is limited not by the placental but by the fetal compartment and that the fetus is capable of synthetizing normal amounts of estrogen precursors from C2 groups even in chronic placental insufficiency. A number of partly new results [5, 7, 14, 15, 21, 22, 23] that cannot be dealt with in detail here support this conclusion. It-may be assumed, at least äs a working hypothesis, that decreased estrogen excretion during pregnancy is probably due to a disturbance in the fetal adrenal or liver and is thus secondary to primary placental insufficiency. Placental sulfatase lack, fetal adrenal hypoplasia arid anencephalus are exceptions, äs mentioned previously. In a similar fashion pregnandiol reflects placental function [l, 2, 8, 9, 10,13]. Not only the fetus but also the placenta is capable of compensating some defects [21] äs witnessed by capillary hyperplasia in hypofunction. This compensation may lead to improved hormone excretion during the further course of pregnancy after a period of low hormone excretion. Such cases are usually called "erroneously pathological" in retrospective. Our model with 4 factors (estrogen = fetus, placenta = pregnandiol, fetal and placental compensation) explains the results of this work. Particularly it seems proven that pregnandiol reflects the nutritive function of the placenta and not some other function that may be unimportant for fetal well being. This Stresses the finding of NAEYE [14] showing that the fetal adrenal cortex and other organs are retarded in weight to a greater extent in intrauterine growth retardation than the birth weights o£ such newborns. Less severe injury to fetal organs could thus be possible without macroscopically visible dystrophy of the fetus: This would explain why in risk group IV only slightly more than half the infants were SGA. This wöttld also lead to thc conclusion that cases in risk group II are to be considered äs at risk and should be treated prophylactically. If we consider it ouraim to diagnose all cases with placental insuf ficiency, if possible before injury to the fetus is severe, then we must not only have hormonal conttol but also hormonal preventive control. We believe that the determination of both estrogen and pregnandiol is a reliable System for this purpose. In our perinatal practice this Interpretation o£ both endocrine parameters has proved of value. A current study indicates that three combined hormone determinations between weeks 20 and 26 are of great value for the prognosis of risk of intrauterine growth retardation. In contrast to many others, e. g. KUSS [12] , we believe that in the future placental parameters such äs pregnandiol will be of considerable significance for the early recognition of chronic placental insufficiency. Early diagnosis will be particularly decisive if and when a reliable therapy is discovered and thus fetal injury is, perhaps, avoided. This i s being studied. Fig. 1) . This can be explained only by assuming that the rate of estrogen excretion is usually not dependent on the placenta but on the capacity of the fetal adrenals and liver. Thus our results indirectly confirm those of others who claim that the fetus can synthetize estrogen precursors without the need for placental pregnenolon by using acetate. Thus it appears that the synthetic pathway that is independent of the placenta at the beginning plays a quantitative role also. Since the placenta can form aromatic compounds even when its nutritive function is severely impaired, our finding is further proof that estrogen excretion reflects fetal and not fetoplacental well-being. It follows that pathological estrogen excretion indicates, fetal injury that has already occurred. The requirement that a sensitive parameter of placental function be hence determined in time is met by pregnandiol assays. Low pregnandiol excretion often precedes low estrogen excretion which leads to a SGAinfant, indicating that pregnandiol excretion i s closely correlated to placental nutritive function.
Synthetic reactions in thc fetus require cnergy and hence dcpend on thc placenta. Normal estrogen excretion frequently observed in the presence of prolonged decreased pregnandiol excretion must hence indicate that the fetus can compensate for placental insufficiency. In the placenta this can be demonstrated by hyperplasia of thc capillaries. This is reflccted in the undulating excretion of pregnandiol (Fig, 1) , where compcnsation (new vcssel formation) and depression (lesion of vessels) make these contradictory placental processes "visible". The functional unity of the fetus and the placenta i s finally also demonstrated by thc fact thateach prolonged compcnsatory phase of thc placenta is responded to by the fetus with a clearly compensatory excretion of estrogen (Fig. 1) . Decreasing pregnandiol excretion, on the other band, is accompanied by Stagnation in estrogen excretion, indicating delayed fetal growth. This paper is the first to demonstrate a relationship between placental morphology and fetoplacental endocrinology. Four risk groups are proposed (Tab. II). The model is based on 4 assumptions: 1. Estrogen excretion is a fetal and not a fetoplacental parameter; 2. Pregnandiol excretion is a parameter of placental nutritive function; 3. Fetal compensatory capacity; 4. Placental compensatory capacity.
The model permits us to Interpret our data. The frequency of SGA infants increases from risk group I (normal excretion of both hormones, no SGA infants), through risk group II (only pregnandiol excretion pathological, 11.5% SGA newborns) and risk group III (only estrogen excretion pathological, 26% SGA infants) to risk group IV (both hormone excretions pathological, 55.4% SGA infants). Thedegree of risk can be estimatcd with our model. Risk group II indicates slight, beginning EPH gcstosis. Treatment in time maintains normal estrogen excretion with frequently low pregnandiol valucs. If control and treatment are neglected the picture frequently changes to group IV and danger to the fetus is considcrably increascd (Fig. 2) .
It is slowly being realized in perinatal medicine that the therapy of chronic placental insufficiency must be prolonged in Order to be successful. Early diagnosis is a prime requirement. Our data show that this is possible in the case of placental insufficiency before fetal damage occurs. This makes early treatment possible. The large number of SGA newborns in clinically apparently normal pregnancies (30.1% of all intrauterine growth retardations) suggests that all pregnancies should be controlled endocrinologically. This can only be realized by cooperation between clinicians and practitioners. Keywords: Endocrine model, intrauterine growth retardation; nutritive placental function, pregnandiol, total estrogen. 
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